Kyowa Kirin R&D PipelineModalities :
What we doState-of-the-art biotechnology
centered on antibody engineering
Areas of focus
Kyowa Kirin is a Japan-based Global Specialty Pharmaceutical Company, contributing to
human health and well-being worldwide through innovative drug discovery and
global commercialization, driven by state-of-the-art antibody technologies,
in the core therapeutic areas of oncology, nephrology,
central nervous system and immunology.
Cutting-edge biotechnology
centered on antibody
engineering technology
Technology-driven drug discovery
The novel drug discovery of Kyowa Kirin is firmly
supported by the exquisite experience and
technologies in research, development and
manufacture of biologics, and by open
innovation.
This unique style of drug discovery is
what we call technology-driven drug discovery,
focused
on the key technologies below.
Main products
Pipeline
Numerous promising pharmaceutical
candidates are emerging from our
development pipelines.
They are the result of our
never-ending efforts in honing the edge of our
state-of-the-art
technologies and deliver
innovation in medical care.
- ※Since the development of KHK6640 for Alzheimer’s Disease was discontinued in Japan and Europe, the relevant information was deleted from this table.
- ※Our main progress from March 31, 2023 are as follows.
- ・We decided to discontinue the development of RTA 402 (generic name: Bardoxolone Methyl) in the nephrology field.
- ・We decided to discontinue the development of ME-401 (generic name: Zandelisib) in the oncology field.
Around the world
Seamless collaboration between regions
ensures timely
delivery of novel medicines
to patients around the world,
enhanced by
close ties to research partners.
Partnerships
We are open and flexible to strategic collaborations
and partnerships
with pharmaceuticals, biotech,
and academia partners.
